Abstracts tagged "prevention"

Abstract Number: 1109 • ACR Convergence 2025
Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study
Laurianne Simard¹, Nathalie Amiable², Ines Colmegna³, Anne-Sophie Julien⁴, Sonia Léger-Thériault⁵, Alexandra Godbout⁴, Lison Fournier⁶, Giuliana Alfonso⁵, Josiane Bourre-Tessier⁷, Marie Hudson⁸, Nicolas Richard⁹, Jean-Paul Makhzoum¹⁰, Arielle Mendel¹¹, Sasha Bernatsky¹², Marc Dionne⁶, Michael Libman⁵, Gaston De Serres⁶ and Paul Fortin¹³, ¹Universite Laval, Quebec, QC, Canada, ²Centre de recherche du CHU de Québec – Université Laval, Quebec City, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Centre de recherche du CHU de Québec – Université Laval, Quebec, QC, Canada, ⁵MUHC, Montreal, Canada, ⁶Centre de recherche du CHU de Québec – Université Laval, Quebec, Canada, ⁷Centre hospitalier de l'Universite de Montreal, Montreal, QC, Canada, ⁸McGill University, Montréal, QC, Canada, ⁹Hopital Maisonneuve Rosemont, Montreal, QC, Canada, ¹⁰Universite de Montreal, Montreal, Canada, ¹¹McGill University Health Centre, Montréal, QC, Canada, ¹²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARD) treated with B-cell-depleting therapies such as rituximab (RTX) have impaired humoral immune responses, increasing their susceptibility to…
Abstract Number: 1982 • ACR Convergence 2025
Bridging the Gap in Underserved Care: A Quality Improvement Initiative to Increase Pneumococcal Vaccination Rates in Immunocompromised Rheumatology Patients
Kuan-Tung Lin¹, Yue Hao², Mai Abdelnabi² and Wai-Hang Jackie Lam², ¹North East Medical Services, San Mateo, CA, ²North East Medical Services, San Francisco, CA
Background/Purpose: Patients with rheumatologic conditions who are on immunosuppressive therapy face an elevated risk of pneumococcal infections, particularly those in medically underserved populations. Per ACR…
Abstract Number: 1061 • ACR Convergence 2025
Screening for Hepatitis B in a Veterans Health Administration Subpopulation with Rheumatological Disease Prior to Initiating Immunosuppressive Therapy: a retrospective study on testing and treatment within the Black American population from the VAMC in Memphis, TN
Daniel Austin¹, Beenish Zulfiqar², Akhil Adla¹, Jeffrey Zuber² and Joshua Sullivan³, ¹University of Tennessee Health Science Center, Memphis, TN, ²University of Tennessee Health Science Center & Lt. Col. Luke J. Weathers, Jr. VA Medical Center, Memphis, TN, Memphis, TN, ³Lt. Col. Luke J. Weathers, Jr. VA Medical Center, Memphis, TN, Memphis, TN
Background/Purpose: Hepatitis B virus (HBV) screening is insufficiently completed prior to initiation of immunosuppressive therapy nationwide. Various factors including alert fatigue, provider mistakes, non-compliance, and…
Abstract Number: 1980 • ACR Convergence 2025
Improving Vaccination Rates in the Rheumatology Clinic
Kajal Patel¹, Sunita Paudyal¹ and Deborah Hurley², ¹Prisma Health, Columbia, ²Prisma Health Midlands, Columbia
Background/Purpose: Influenza and pneumococcal infection can cause mild to severe illness and potentially lead to serious complications or death. Patients with rheumatic diseases have weakened…
Abstract Number: 1034 • ACR Convergence 2025
Healthy Dietary Patterns and Risk of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Elena Joerns¹, Jeffrey Sparks², Cynthia Chelf¹, Cynthia Crowson³, John Davis¹ and Vanessa Kronzer¹, ¹Mayo Clinic, Rochester, MN, ²Brigham and Women's Hospital, Boston, MA, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Healthy dietary patterns are associated with many health benefits, including lower cardiovascular disease, mortality, and rheumatoid arthritis (RA) disease activity. Therefore, we aimed to…
Abstract Number: 1934 • ACR Convergence 2025
Analysis of the Determinants of Vaccine Acceptance and Hesitancy in Germany: A Mixed-Methods Approach Incorporating Health Insurance Data and Qualitative Interviews with Patients and Physicians
Maria Zacharopoulou¹, thomas Grüter², Heike van de Sand³, Romy Lauer⁴, Marianne Tokic⁵, Jale Basten⁵, Robin Denz⁵, Anastasia Suslow⁶, Andreas Stallmach⁷, Anika Franz⁷, Theresa Oganowski², Ina Otte⁶, Ingo Meyer³, Horst Christian Vollmar⁶, Nina Timmesfeld⁵, Ursula Marschall⁸, Joachim Saam⁸, Kerstin Hellwig² and Uta Kiltz⁹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²St. Josef Hospital, Ruhr University Bochum, Germany, Bochum, Germany, ³PMV research group, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany, Cologne, Germany, ⁴Institute of General Practice and Family Medicine, Ruhr-University Bochum, Bochum, Germany, ⁵Department of Medical Informatics, Biometry, and Epidemiology, Ruhr University Bochum, Germany, Bochum, Germany, ⁶Institute of General Practice and Family Medicine (AM RUB), Medical Faculty, Ruhr University Bochum, Germany, Bochum, Germany, ⁷University Hospital Jena, Germany, Jena, Germany, ⁸BARMER Institute for Health System Research, Department Medicine and Health Services Research, Wuppertal, Germany, Wuppertal, Germany, ⁹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Adequate immunization is essential for patients with inflammatory rheumatic and musculoskeletal diseases (iRMD). Autoimmunity itself and immunotherapy increase the risk of infection independent of…
Abstract Number: 1023 • ACR Convergence 2025
Comparative Analysis of Oral Health and Dental Care in Patients With Immune-Mediated and Non-Immune-Mediated Rheumatic Diseases
Margarita Isabel Alarcon-Jarquin¹, Fernanda M. Garcia-Garcia², Vanessa L. Lopez-Flores¹, Aranxa Galindo-Bandt³, Mario A. Arellano-Alvarez³, Aleydis Gonzalez-Melendez³, Gabriel Figueroa-Parra³, Dionicio A. Galarza-Delgado² and Janett C. Riega-Torres⁴, ¹Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Oral health impairment is common in patients with immune-mediated rheumatic diseases (IMRDs) due to chronic inflammation and immune dysregulation. These complications can worsen systemic…
Abstract Number: 0454 • ACR Convergence 2024
Evaluating the Rate of Cervical Cancer Screening and HPV Vaccination in Women with Systemic Lupus Erythematosus Within a Large Urban Healthcare System
Alana Haussmann¹, Eunice Adu Dapaah², John FitzGerald² and Maureen McMahon³, ¹University of California Los Angeles, Santa Monica, CA, ²UCLA, Los Angeles, CA, ³UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Prior research has outlined an increased incidence of cervical dysplasia and cervical cancer in women diagnosed with systemic lupus erythematosus (SLE). These individuals face…
Abstract Number: 2285 • ACR Convergence 2024
Safety and Tolerability of a Combination of Curcumin, Omega-3 and Vitamin-D: Results from the PASCOD Study, an RA Prevention Protocol
Halle Cochrane, Caitlin Mcfadyen, Kale Mayor, Rhonda Silva, Kristin James, Xiaobo Meng, Dylan Mackay, Hani El-Gabalawy and Liam O'Neil, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Rheumatoid Arthritis (RA) is a progressive inflammatory autoimmune disease affecting 1% of the global population for which there is currently no cure. Recent research…
Abstract Number: 0535 • ACR Convergence 2024
Oral Glucocorticoid Premedication Is at Least as Effective as Intravenous Glucocorticoid Premedication for Prevention of Infusion-related Reactions to Rituximab in Rheumatoid Arthritis Patients
Pauline Bovens¹, Luuk Van Esveld², Maike Wientjes¹, Noortje van Herwaarden³, David Ten Cate⁴, Eward Melis³, Nienke Lesuis⁵, Bart van den Bemt⁶ and Alfons den Broeder¹, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²Sint Maartenskliniek, Utrecht, Netherlands, ³Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Sint Maartenskliniek, Rotterdam, Netherlands, ⁵Hospital Group Twente, Almelo, Netherlands, ⁶Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands
Background/Purpose: It has been demonstrated that pretreatment with intravenous glucocorticoids can prevent infusion-related reactions (IRR) that may occur in RA patients receiving rituximab infusions [1].…
Abstract Number: 2414 • ACR Convergence 2024
A Retrospective Comparative Analysis of Cardiovascular Risk Factors, Atherosclerotic Cardiovascular Disease and Statin Use as Secondary Prevention in a Cohort of Patients with Systemic Lupus Erythematosus versus Without Rheumatological Disease from a Single-Center Patient Registry
Alma Aveytia Camacho¹, Rakesh Gullapelli², Vineetha Philip³, Soudabeh Daliri¹, Ruba Memon⁴, Helene DiGregorio², Lily Romero Karam², Kanika Monga³, Eleonora Avenatti², Khurram Nasir² and Myriam Guevara¹, ¹Houston Methodist, Houston, TX, ²Houston Methodist Hospital, Houston, TX, ³Houston Methodist Hospital, Sugar Land, TX, ⁴Houston Methodist, Missouri City, TX
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased prevalence of cardiovascular risk factors (RFs), which predispose to higher risk of premature atherosclerotic cardiovascular disease…
Abstract Number: 0701 • ACR Convergence 2024
Diagnostic Performances of Vascular Biomarkers Soluble Fms-like Tyrosine Kinase (sFlt-1) and Placental Growth Factor (PlGF) in Scleroderma Renal Crisis: A Case Control Study
Aïcha Kante¹, Paul Legendre², Bérangère Joly³, bertrand Dunogue⁴, Alexandre Hertig⁵, Benjamin Terrier⁶, Elodie Massolin⁷, Felix Ackermann⁸, Luc Mouthon⁴, Jean Guibourdenche⁹ and Benjamin Chaigne¹⁰, ¹Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Université Paris Cité, Paris, Ile-de-France, France, ²Service immunologie clinique, Centre hospitalier du Mans, Le Mans, France, Le Mans, ³Service d'Hématologie Biologique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris (APHP.Nord), Université Paris Cité, Paris, Ile-de-France, France, ⁴Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁵Department of Nephrology, Hôpital Foch, Suresnes, France, Suresnes, Ile-de-France, France, ⁶Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ⁷UF d'Hormonologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, Paris, Ile-de-France, France, ⁸Department of Internal Medicine, Foch Hospital, Suresnes, France., Suresnes, France, ⁹APHP-CUP, Hôpital Cochin, F-75014 Paris, Université Paris Cité, Paris, Ile-de-France, France, ¹⁰Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France
Background/Purpose: Scleroderma renal crisis (SRC) is a major vascular complication of systemic sclerosis (SSc), associated with high morbidity and mortality. Few biomarkers are available to predict…
Abstract Number: 2433 • ACR Convergence 2024
Sequential Pneumococcal Vaccination in SLE: Immunogenicity, Side Effects and Comparison with PPSV23 Vaccination
Rudrarpan Chatterjee¹, Sai Yasaswini Kommaraju², Shincy MR³ and Amita Aggarwal⁴, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow., Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ³Central research lab, Kampewgowda Institute of Medical Sciences, Bengaluru, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: SLE patients have increased risk of invasive pneumococcal disease due to immune dysregulation and drugs used in these patients. EULAR 2019 recommendation suggest sequential…
Abstract Number: 0844 • ACR Convergence 2024
Effectiveness and Safety of the Recombinant Zoster Vaccine in Patients ≥18 Years of Age with Systemic Lupus Erythematosus or Multiple Sclerosis
Sheryl Kluberg¹, Sophie E. Mayer², O’Mareen Spence³, Driss Oraichi⁴, Harry Seifert⁴, Omar Ali³, Huifeng Yun⁴, Andrew L. Simon⁵, Jenice S. Ko⁶, Caroline Hugh⁷, Meg Her⁷, Kathleen Shattuck⁷, Richard Platt⁸, Aziza Jamal-Allial⁹, Djeneba Audrey DJIBO¹⁰, Kimberly Daniels¹¹, Qianli Ma¹², Cheryl N McMahill-Walraven¹⁰, Rachel P. Ogilvie¹³, Kristin Palmsten¹⁴, Mano Selvan¹⁵, Najat Ziyadeh¹⁶, Alexis Ogdie¹⁷ and Michael George¹⁸, ¹Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, ²Harvard Pilgrim Health Care Institute, Durham, ³GSK, Rockville, ⁴GSK, Rockville, MD, ⁵Harvard Pilgrim Healthcare Institute, Boston, MA, ⁶Harvard Pilgrim Health Care Ins􀆟tute, Boston, MA, ⁷Harvard Pilgrim Health Care Institute, Boston, MA, ⁸Harvard Pilgrim Health Care Institute / Harvard Medical School, Boston, MA, ⁹Carelon Research, Elevance Health, Newton, ¹⁰CVS Health, Blue Bell, ¹¹Carelon Research, Elevance Health, Wilmington, ¹²Humana Healthcare Research, Inc., Louisville, ¹³Optum, Boston, MA, ¹⁴HealthPartners Institute, Minneapolis, ¹⁵Humana Healthcare Research, Sugar Land, Texas, ¹⁶Optum, Baltimore, MD, ¹⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ¹⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: The recombinant zoster vaccine (RZV) is US Food and Drug Administration-approved for the prevention of herpes zoster (HZ, shingles) in adults ≥50 years, and…
Abstract Number: 2588 • ACR Convergence 2024
Examining the Influence of Socioeconomic Status on Osteoarthritis Prevalence and Risk Factors Among New York Residents
Titilayo Adeniran¹, David Cecil² and Ahinee Amamoo³, ¹Hospital for Special Surgery (HSS), New York, NY, ²Samford University, Birmingham, ³Samford University, Birmingham, AL
Background/Purpose: Osteoarthritis (OA) is a chronic, progressive condition affecting the musculoskeletal system, significantly impacting the quality of life and mobility of millions worldwide. It is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].